medipharm logo.jpg
European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs
05 oct. 2020 05h55 HE | MediPharm Labs Corp.
A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large pharmaceutical company commercializing medical cannabis productsPartnership validates...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
09 sept. 2020 07h45 HE | BioNTech SE
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer und BioNTech geben potenzielle Liefervereinbarung mit der EU über 200 Millionen Dosen von mRNA-basierten Impfstoffkandidaten gegen SARS-CoV-2 bekannt
09 sept. 2020 06h15 HE | BioNTech SE
Die geplante Vereinbarung umfasst die Lieferung von 200 Millionen Impfstoffdosen sowie eine Option zum Erwerb von zusätzlichen 100 Millionen Dosen; Lieferung soll Ende 2020 starten, vorbehaltlich der...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
09 sept. 2020 06h15 HE | BioNTech SE
The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Biopharma Leaders Unite to Stand with Science
08 sept. 2020 06h30 HE | BioNTech SE
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines NEW YORK, Sept. 08, 2020 ...
logo.png
Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients
01 sept. 2020 08h00 HE | Arch Biopartners
TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo-alt.png
Global Systemic Lupus Erythematosus Market – Estimated to Gain Traction with Arrival of Key Pipeline Agents, with Promising Higher Efficacy than Existent Therapies - PMI
20 août 2020 10h35 HE | PMI
Covina, CA, Aug. 20, 2020 (GLOBE NEWSWIRE) -- The report "Global Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics),...
logo.png
Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST
18 août 2020 08h16 HE | Arch Biopartners
TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
14 août 2020 07h30 HE | ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
logo-alt.png
Global Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market
13 août 2020 10h34 HE | PMI
Covina, CA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- The report "Global Neurodegenerative Disorder Therapeutics Market, By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis,...